European Training Network for Integrated Training in Dry Eye Disease Drug Development


IT_DED Curie_actions
Acronym IT-DED³
Call for proposal H2020-MSCA-ITN-2017
Grant agreement No 765608
Implementation period 01.01.2018. – 31.12.2021.
Project coordinator University of Antwerp, Belgium
Project partners Sorbonne Université, France
Latvian Institute of Organic Synthesis, Latvia
 University of Valladolid, Spain
 University of Eastern Finland, Finland
 University Hospital Cologne, Germany
 Institute of Experimental Biology and Technology, Portugal
Project web page
Leader of Latvian team Prof. Aigars Jirgensons
Total Costs 3 002 689.44 EUR
EU contribution 3 002 689.44 EUR
Costs for  Latvian partner 223 577.64 EUR


The major research objective of the IT-DED³ project is to accelerate new therapy and biomarker development in the field of the dry eye disease (DED) by creating a multidisciplinary European research and training network around DED research.

IT-DED3 will handle different therapeutic approaches for DED treatment such as synthesized and upscaled small molecules (serine protease and RIPK1 inhibitors, natural compounds) and will develop innovative drug delivery systems, which will be tested in validated and newly developed in vivo models for DED. For patient stratification, which is highly needed in the field of DED, we will identify new biomarkers and develop innovative imaging techniques in both animal models and in humans.

IT-DED3 constitutes a unique platform for a true translational research dedicated to patients suffering from DED and is able to translate basic research into patient applications (‘bench-to-bedside’ principle).